LSB logo

LakeShore Biopharma (LSB) Financials

Balance sheets

30 Sept 202330 June 202301 Sept 202201 June 202201 Mar 2022

Total Assets

$220.8 M(-5.2%)$233.0 M(+7.2%)$217.3 M-$226.8 M

Current Assets

$128.1 M(-7.7%)$138.7 M(+13.4%)$122.3 M-$120.3 M

Non Current Assets

$92.7 M(-1.6%)$94.3 M(-0.8%)$95.0 M-$106.5 M

Total Liabilities

$144.5 M(+1.8%)$141.9 M(-59.5%)$350.7 M-$336.7 M

Current Liabilities

$90.9 M(+1.1%)$89.8 M(+11.3%)$80.7 M-$74.9 M

Long Term Liabilities

$53.6 M(+3.0%)$52.0 M(-80.7%)$270.0 M-$261.9 M

Shareholders Equity

$76.4 M(-16.2%)$91.1 M(+168.3%)-$133.4 M--$109.9 M

Book Value

$76.4 M(-16.2%)$91.1 M(+168.3%)-$133.4 M--$109.9 M

Working Capital

$37.2 M(-23.9%)$48.9 M(+17.6%)$41.6 M-$45.4 M

Cash And Cash Equivalents

$35.6 M(+172.7%)$13.1 M(-59.0%)$31.8 M-$42.6 M

Accounts Payable

$11.6 M(+14.4%)$10.2 M(+94.1%)$5.2 M-$4.8 M

Accounts Receivable

$58.8 M(-13.9%)$68.4 M(+4.0%)$65.7 M-$48.5 M

Short Term Debt

$25.7 M(+5.7%)$24.4 M(+3.8%)$23.5 M-$18.3 M

Long Term Debt

$50.2 M(+4.1%)$48.2 M(+16.8%)$41.3 M-$41.6 M

Total Debt

$76.0 M(+4.6%)$72.6 M(+12.1%)$64.8 M(+100.0%)$0.0(-100.0%)$59.9 M

Debt To Equity

1.0(+25.6%)0.8(+266.0%)-0.5--0.5

Current Ratio

1.4(-8.4%)1.5(+2.0%)1.5-1.6

Quick Ratio

1.1(-13.5%)1.3(+2.4%)1.2-1.3

Inventory

$29.2 M(+16.0%)$25.1 M(+10.8%)$22.7 M-$26.2 M

Retained Earnings

-$280.8 M(-4.8%)-$267.9 M(-14.1%)-$234.9 M--$250.2 M

PB Ratio

1.0(-30.5%)1.4---

Income statements

30 Sept 202330 June 202301 Sept 202201 June 202201 Mar 2022

EPS

-$1.6(-46.8%)-$1.1(-131.1%)-$0.5(+48.0%)-$0.9-

TTM EPS

-$2.6(-72.3%)-$1.5(-13.3%)-$1.3(-52.0%)-$0.9-

Revenue

$13.4 M(-46.8%)$25.2 M(-11.2%)$28.3 M(-8.9%)$31.1 M-

TTM Revenue

$38.5 M(-27.9%)$53.5 M(-10.0%)$59.4 M(+91.1%)$31.1 M-

Total Expenses

$27.2 M(-22.1%)$34.9 M(+34.7%)$25.9 M(-21.1%)$32.9 M-

Operating Expenses

$24.8 M(-17.4%)$30.0 M(+52.0%)$19.7 M(-21.5%)$25.1 M-

Cost Of Goods Sold

$2.4 M(-51.1%)$4.9 M(-20.4%)$6.2 M(-19.7%)$7.7 M-

TTM Cost Of Goods Sold

$7.4 M(-34.0%)$11.2 M(-20.0%)$13.9 M(+80.3%)$7.7 M-

Gross Profit

$11.0 M(-45.8%)$20.2 M(-8.6%)$22.1 M(-5.3%)$23.3 M-

TTM Gross Profit

$31.2 M(-26.4%)$42.3 M(-6.9%)$45.5 M(+94.7%)$23.3 M-

Gross Margin

81.9%(+2.0%)80.3%(+2.9%)78.1%(+3.9%)75.1%-

Operating Profit

-$13.8 M(-41.3%)-$9.8 M(-509.9%)$2.4 M(+234.4%)-$1.8 M-

TTM Operating Profit

-$23.6 M(-219.2%)-$7.4 M(-1310.0%)$611.4 K(+134.4%)-$1.8 M-

Operating Margin

-103.3%(-165.6%)-38.9%(-561.6%)8.4%(+247.6%)-5.7%-

Net Income

-$14.5 M(-46.2%)-$9.9 M(-902.7%)$1.2 M(+141.7%)-$3.0 M-

TTM Net Income

-$24.4 M(-181.2%)-$8.7 M(-402.7%)-$1.7 M(+41.7%)-$3.0 M-

Net Margin

-108.4%(-174.8%)-39.5%(-1004.8%)4.4%(+145.7%)-9.5%-

EBIT

-$13.6 M(-53.3%)-$8.9 M(-473.3%)$2.4 M(+235.2%)-$1.8 M-

TTM EBIT

-$22.4 M(-246.1%)-$6.5 M(-1149.3%)$618.2 K(+135.2%)-$1.8 M-

EBITDA

-$13.6 M(-53.3%)-$8.9 M(-473.3%)$2.4 M(+235.2%)-$1.8 M-

TTM EBITDA

-$22.4 M(-246.1%)-$6.5 M(-1149.3%)$618.2 K(+135.2%)-$1.8 M-

Selling, General & Administrative Expenses

$15.8 M(-0.3%)$15.8 M(+4.5%)$15.2 M(+4.3%)$14.5 M-

TTM SG&A

$31.6 M(+2.1%)$31.0 M(+4.4%)$29.7 M(+104.3%)$14.5 M-

Depreciation And Amortization

$2.8 M-$2.5 M--

TTM D&A

$2.8 M-$2.5 M--

Interest Expense

$953.2 K(-16.8%)$1.1 M(+0.1%)$1.1 M(+2.6%)$1.1 M-

TTM Interest Expense

$2.1 M(-8.4%)$2.3 M(+1.3%)$2.3 M(+102.6%)$1.1 M-

Income Tax

-$32.4 K(+61.2%)-$83.6 K(-1129.4%)-$6800.0(-107.3%)$92.6 K-

TTM Income Tax

-$116.0 K(-28.3%)-$90.4 K(-205.4%)$85.8 K(-7.3%)$92.6 K-

PE Ratio

-----

PS Ratio

1.9(-19.6%)2.4---

Cashflow statements

30 Sept 202330 June 202301 Sept 202201 June 202201 Mar 2022

Cash From Operations

-$20.2 M--$15.7 M--

TTM CFO

-$20.2 M--$15.7 M--

Cash From Investing

-$3.2 M--$2.8 M--

TTM CFI

-$3.2 M--$2.8 M--

Cash From Financing

$6.2 M-$7.6 M--

TTM CFF

$6.2 M-$7.6 M--

Free Cash Flow

-$23.4 M--$18.5 M--

TTM FCF

-$23.4 M--$18.5 M--

CAPEX

$3.3 M-$2.8 M--

TTM CAPEX

$3.3 M-$2.8 M--

Dividends Paid

-----

TTM Dividends Paid

-----

TTM Dividend Per Share

-----

TTM Dividend Yield

-----

Payout Ratio

-----